Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Opioid-Related Disorders 1Lymphoma, Follicular 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Barrett Esophagus 1

Interventions

Rituximab 90Cyclophosphamide 30Lenalidomide 28Bendamustine Hydrochloride 24Prednisone 20Vincristine 19obinutuzumab 17Doxorubicin 16fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Deoxycholic Acid 9parsaclisib 8Prednisolone 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × X-Rays × Clear all
NCT05251376 2023-01-19

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

Lyndra Inc.

Phase 1 Withdrawn
Lymphoid

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡